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ABSTRACT 
 
 
 MicroRNAs (miRNAs) are non-coding double stranded RNA molecules known to 
regulate gene expression. The recent discovery that the miR-30 family of miRNAs 
overexpress in mouse breast cancer tumor cells in the same regions commonly seen in 
human breast cancer tumor cells, has lead us to design a system for over-expressing these 
miRNAs to help evaluate their role in tumorigenesis.  In this study, genes encoding miR-
30c1, c2, a, and d, were successfully cloned. The gene for miR-30c1 was further 
investigated in a tet inducible expression system.  Fluorescence data indicated HEK-293 
cells were successfully transfected with expression plasmid, and qRT-PCR on HEK-293 
RNA indicated miR-30c1 levels increased. 
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BACKGROUND 
 
MicroRNAs:  Structure and Function 
  
 MicroRNAs (miRNAs) are recently discovered small non-coding RNAs that are 
21-23 nucleotides long. The majority of miRNA genes are located in introns of protein 
coding genes (PCGs) or in intergenic non-protein-coding transcription units (Lee et al., 
2004). They were first described as two small lin-4 transcripts of approximately 22 and 
61 nucleotides, that were identified in C. elegans and found to contain sequences 
complementary to a repeated sequence element in the 3′ untranslated region (UTR) of lin-
14 mRNA, suggesting that lin-4 regulates lin-14 translation via an antisense RNA-RNA 
interaction (Lee et al., 1993). These small RNAs were found to function in the down 
regulation of the lin-14 protein.  At first they were called small RNAs, and only in 2001 
were they named miRNA for their small nucleotide structures. 
  miRNAs are formed initially in the nucleus by RNA polymerase II transcribing 
the miRNA gene (Figure-1), which creates primary miRNA (pri-miRNA), a 33 
nucleotide stem structure and a terminal loop (Lee et al., 2004). This 70 base pair stem-
loop structure is then cleaved by a Drosha-DGCR8 complex which creates the 70 
nucleotide long pre-miRNAs.  The DGCR8 group also known as Pasha can specifically 
identify and bind to pri-miRNAs (Rana, 2007). 
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Figure-1:  Transcription of miRNAs.  miRNAs are initially 
formed in the nucleus by RNA polymerase II to create a primary 
miRNA (pri-miRNA) (diagram lower) (Lee et al., 2004). 
 
 Once the pre-miRNAs are created, they are transported out of the nucleus by a 
nuclear transport receptor complex, and are then received by Dicer in the cytoplasm 
(Figure-2).  Dicer cleaves the stem-loop into ~22 nucleotide long mature miRNAs. The 
miRNAs are then loaded on to the RNA-induced silencing complex, RISC, which alludes 
to one of the main functions of miRNA, gene-silencing (Chendrimada et al., 2005; Rana, 
2007).  The RISC complex is a multi-protein complex that uses siRNA as a template to 
degrade the sense strand, leaving an antisense miRNA.  Once a miRNA binds its 
complementary mRNA, it cleaves the mRNA with RNase thus silencing its expression 
into protein (Zamore et al., 2000). 
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Figure-2: Formation of Mature miRNAs.  Following 
transcription, pri-miRNAs are transported out of the nucleus and 
are received by Dicer that cleaves the stem-loop into ~22 
nucleotide long mature miRNAs. 
 
  After being transferred onto the RISC complex, the miRISC identifies a matched 
target gene and the miRNA binds to the 3’ UTR of the gene. The portion of the miRNA 
that binds to the target gene is known as the seed region. The seed region is 2-8 
nucleotides long and dictates how families of miRNAs are formed. When a miRNA binds 
to its target gene in mammals, translational repression occurs in which translation is 
blocked and mRNA is conserved. In plants it is more commonly seen that miRNA 
cleaves mRNA and the mRNA becomes degraded (Bartel 2004).    
 Some of the other functions found for miRNAs are cell proliferation, 
development, metastasis and apoptosis.  Due to these additional functions, recent research 
has focused on their role in oncogenesis and tumor suppression. 
 
Role of MicroRNAs in Cancer 
 Some miRNA families have been proven to be associated with specific cellular 
functions, such as control of cell proliferation (miR-125b and let-7), hematopoietic B-cell 
lineage fate (miR-181), B-cell survival (miR-15a and miR-16-1), brain patterning (miR-
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430), pancreatic cell insulin secretion (miR-375), and adipocyte development (miR-143) 
(Harfe, 2005).   Those miRNAs that stimulate cell proliferation may also be associated 
with cancer.  
 Some miRNAs have been studied for their tumor suppressor and oncogenic 
qualities, such as miR-21, which is considered an oncogenic miRNA.  It has been found 
to be overexpressed in breast cancer. Some miRNAs are also associated with more than 
one type of cancer, as in the case for miR-21 which was also discovered to be elevated in 
glioblastoma, VMP1 neuroblastoma primary tumors, and tumor cell lines (Calin and 
Croce 2006).  Two families of miRNA that have been discovered to be tumor suppressors 
are the miR-16-1-15a cluster which is down-regulated or completely deleted in B-cell 
chronic lymphocytic leukemias (Negrini et al, 2007).  Figure-3 shows a representation of 
miRNAs acting as tumor suppressors and oncogenes. 
 
Figure-3: Diagram of Several miRNA Families Acting As Tumor 
Suppressors.  (Wang and Wu 2007). 
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 miRNAs and protein coding genes interact with each other to either form tumor 
suppressor proteins or oncogenic proteins. The abnormalities found in cancer to influence 
the activity of miRNAs are the same as those described to target PCGs.  Inactivation of 
tumor suppressor PCGs and activation of oncogenic miRNAs cause reduced levels of 
proteins blocking proliferation and activating apoptosis. Activation of oncogenic PCGs 
and inactivation of suppressor miRNAs are followed by accumulation of proteins that 
stimulate proliferation and decrease apoptosis (Calin and Croce, 2006).  
 
Figure-4:  MicroRNAs Can Be Tumor Stimulators or 
Repressors.  Shown is a comparison of the role of miRNAs as 
tumor stimulations (diagram top) or tumor suppressors (diagram 
lower) (Calin et al., 2006). 
 
Role of MicroRNAs in Breast Cancer 
 The cancer of particular interest for this project is breast cancer, since it is one of 
the leading causes of death in women.  Breast cancer occurs 100 times more in women 
than in men.  Some of the causes of breast cancer are mutations in the BRAC1, BRAC2, 
or TP53 genes which are normally tumor suppressor genes, or the presences of the HER-
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2/ErbB2 oncogene.  ErbB2 is an estrogen receptor whose presence is an established 
breast cancer subtype. The degree of breast cancer is heavily dependent on amount of 
tumor suppressor genes the person has that are not mutated.  
 The findings that miRNAs have a role in human cancer is further supported by the 
fact that >50% of miRNA genes are located at fragile site regions, and regions of deletion 
or amplification that are genetically altered in human cancer (Iorio et al., 2005). It has 
also been recognized that miRNA expression might lead to the initiation of cancer 
becoming malignant, in that overexpressed oncogenic miRNAs are located in amplified 
regions found in tumors, and down-regulated suppressor miRNAs are located in regions 
deleted in cancers (Calin and Croce 2006). 
  In one study, miRNA microarrays were utilized to observe miRNA expression 
profiling in a large set of normal and tumor breast tissues demonstrating the existence of 
a breast cancer–specific miRNA signature.  The levels of miRNA in normal tissue and 
breast carcinomas were analyzed to confer that multiple miRNA families are involved in 
breast cancer progression (Figure-5) (Iorio et al., 2005).  The expression levels of let-7a, 
miR-10b, miR-125a, miR-125b and miR-145 are higher in normal epithelial cells relative 
to breast tumors; whereas, miR-21, miR-155, miR-206, miR-122a, and miR-210 are 
higher in breast tumors compared to normal tissues (Wang and Wu, 2007). 
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Figure-5:  Key Candidate miRNAs in Breast Cancer (Iorio et al., 2005). 
 
 However, most miRNAs are expressed at lower levels in breast tumors than 
normal tissues.  Moreover, miRNA levels are lower in poorly differentiated breast tumors 
compared to highly differentiated breast tumors.  As mentioned before, the miRNA 
profile is more accurately correlated with cell differentiation.  By comparing the 
differentiation levels of miRNA in tumor cells, it can be speculated that their levels are 
affected by methylation and demethylation of miRNA promoter regions during cancer 
development.  However the miRNA may mutate in breast cancer, which may affect the 
detection of expression. Thus genomic instability, epigenetic change, and mutation of 
miRNA all cause miRNA dysregulation in breast cancer (Wang and Wu, 2007). 
 Another correlation has been found between subsets of miRNA expression and 
estrogen receptor expression. Especially in determining ErbB2-positive/ER positive and 
ErbB2-positive/ER-negative breast cancers. This can become a useful diagnostic tool for 
prognostic biomarkers for breast cancer (Wang and Wu, 2007). 
 One of the target pathways of miRNAs is the TGF-β signaling pathway. This 
inhibitory pathway is involved in inducing cell-cycle arrest in part through suppression of 
c-Myc-mediated gene expression.  c-Myc is a well known breast cancer oncogene, and 
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the ectopic expression of c-Myc nullifies TGF-β-mediated growth inhibition.  It is 
hypothesized that overexpression of miR-21 inhibits the TGF-β gene, diminishing the 
inhibitory effect of TGF-β signaling, enhancing cell growth, and promoting breast cancer 
development (Wang and Wu, 2007).  
The miR-30 Family 
 The family of miRNAs chosen for this project is the miR-30 family.  miR-30s are 
all down-regulated in both estrogen receptor-negative and progesterone receptor–negative 
tumors, suggesting that expression of these miRNAs is regulated by these hormones 
(Iorio 2005), and suggesting they bind to the mRNAs of cell proliferation proteins to 
decrease their expression in normal cells.  Due to this family’s links to ERbB2 receptors 
and the p53 tumor suppressor (Sachdevaa et al., 2009), further investigation of this family 
of miRNAs was initiated in the Simin lab breast cancer mouse models.  This miR-30 
family was also picked for the genes it targets which are involved in cell proliferation and 
metastasis and its accumulation in epithelial and mesenchymal breast cancer tumor cell 
types which it was originally found. 
 The breast cancer mouse models created in our lab consist of two different types, 
“double negative” and “triple negative”.  The “double negative” mice have Rb and p53 
knockouts, while the “triple negative” mice have mutations of BRAC1, Rb and p53. All 
of the genes that have been knocked out of the mice are tumor suppressor genes, thus 
they readily develop breast cancer tumors.  Figure-6 shows micrographs of example 
tumors from the double knockout mice. 
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Figure-6:  Micrographs of Tumors from Double Knockout Mice. 
Left panel shows adenocarcinomas, middle panel shows spindloid 
tumor, and the right panel shows both tumors side by side.  40X 
magnification.  
 
 The miR-30 family of miRNA has been located in two tumor cell types in the 
mouse models, particularly in epithelial solid tumor types (adenocarcinomas) and 
mesenchymal spindloid tumors. The mouse models develop both types of tumors in 
breast tissue.  In a past study, miR-30c2 was found to be a member of a common 
expression signature characterized in several solid cancers (Calin and Croce, 2006).  In 
our “triple negative” mice, high cellular levels of expression of miR-30a-e were found in 
both tumor types (unpublished work Simin 2005).  However, in the “double negative” 
mice the miR-30 family was found in low levels of expression in both tumor types.  Thus, 
our preliminary data indicate miR-30 family members can be up or down regulated 
depending on the specific miRNA in breast cancer progression. 
  
Target Scan Software 
 Mir “seed regions” are 2-8 bp long domains of a miR that bind by 
complementary base-pairing to the 3’UTR of the target mRNA to induce its dormancy or 
degradation.  Target Scan is an algorithm that helps identify seed regions, and predicts 
miRNA gene targets using the mer system which matches the seed regions of particular 
miRNAs to gene sequences.  When testing a variety of miRs, the more highly conserved 
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a nucleotide sequence at a particular domain, the more likely that domain is its seed 
sequence that binds to that gene to downregulate it.   
The Simin lab used Target Scan to find the seed regions and target genes of the 
miR-30 family.  The search indicated that RUNX2 and metadherin mRNAs likely bind 
this family.   RUNX2 and metadherin are involved in cell proliferation and metastasis, 
thus one working model for the miR-30’s is their levels likely diminish in tumors (in 
agreement with Iorio 2005 who showed miR-30s are all down-regulated in both estrogen 
receptor-negative and progesterone receptor–negative tumors).  Low miR-30 levels in 
tumors would increase the cellular levels of RUNX2 and metadherin to stimulate cell 
proliferation.  Its strong expression in normal tissue could act to downregulate the 
RUNX2 and metadherin proliferation stimulators. 
 
Creation of the tet-Regulated miR Expression System 
 The purpose of this project was to create an inducible expression system to 
investigate the effect of overexpressing specific microRNAs in a cell.  Since the effects 
of over-expression could be detrimental to a cell, an inducible system was devised to 
control the time at which miR expression is induced.  In addition, an inducible system 
would allow the effects of various doses of miR to be determined, or to determine the 
effects of long term miR-30 expression on a cell.   
 In a previous study using a miR-30a backbone, previous investigators were able 
to achieve a tet-regulated system from a U6 promoter (Zhou et al., 2008). The 
transcriptional activity of Tet-regulatable U6 promoter was tightly regulated using 
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Tetracycline.  Repeats of a Tetracycline Operator sequence were introduced within the 
promoter regions and also between U6 promoter and miRNA gene (Zhou et al., 2008). 
 Thus for our study, the vector chosen to be apart of the tet-regulation system was 
pTRE-Tight-DsRed2 (Figure-7).  This plasmid has a tet-responsive element (TRE) that 
activates expression of any gene inserted downstream when a high enough concentration 
of a tetracycline transactivator (tTA) protein is present (Figure 8). The tTA-responsive 
plasmid has a built-in reporter, Tight-DsRed2 (TRITC), which glows red under 
fluorescence when taken up by cells.   The expression of this reporter is also under 
control of the TRE element, so it is also induced by tTA. 
 
Figure-7: Diagram of the CloneTech tTA-Responsive Plasmid. 
 
 The Tet-responsive plasmid is used in tandem with a second plasmid encoding a 
tetracycline transactivator (tTA) (Figure-8). When plasmid pTet-On is used, the tTA is 
expressed only in the presence of Tet or Dox.  In the presence of Tet or Dox, tTA is 
synthesized, which binds the TRE element of the reporter plasmid to induce expression of 
the miR and DsRed2.  When plasmid pTet-Off is used, tTA is constitutively expressed, 
which causes constitutive expression of the miR and the DsRed2.   
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Figure-8: Diagram of the tTA Plasmids pTet-On and pTet-Off by ClonTech. 
 
Using this dual plasmid system allows control of the miR synthesis, which should 
be a superior approach to previous studies in which the miR RNA was directly 
transfected, since the oligos in the latter technique can be rapidly degraded.   
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PROJECT PURPOSE 
 
 
 
 The purpose of this project was to create a tet-regulated system to control 
expression of miR-30 microRNAs in cancer cells, which could eventually be used to gain 
insight of the functions of microRNAs in their role in breast cancer.  In order to test this, 
four genes encoding miR-30c1, c2, a, and d, were cloned from MDA-213 DNA using 
PCR.  The DNA for miR-30c1 was then cloned into a TRE-responsive expression vector, 
then transfected into a human embryonic kidney cell line (HEK-293) and a derived breast 
cancer cell line (MDA-213).  Plasmid pTet-On encoding an active tetracycline 
transactivator (tTA) was also transfected into the cells, to interact with (stimulate) the tet-
responsive element of the plasmid. Once transfected, doxycycline was added to the cells 
to induce expression of the tTA, which upregulates miR-30c1 expression within in the 
cells.  Once the cells are successfully transfected, the DsRed2 reporter will fluoresce red 
in the presence of Tet or Dox as a measure of transfection efficiency.  Real Time Reverse 
Transcriptase PCR will then be performed to quantitate the amount of miR-30c1 RNA 
present in the cells. 
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METHODS 
 
Cloning 
 
PCR Amplification of MiR-30c1  
 
 miR-30c1 was chosen as the insert for this experiment because of its presence in 
breast cancer tumor cells, and its target mRNAs were identified by the Target Scan 
software.  This insert had to be amplified for use in further experiments. The DNA 
encoding mir-30c1 was amplified by PCR from MDA-231 genomic DNA in the 
following reaction: 1.6 µl dNTPs, 0.4 µl of both forward and reverse primers, 1.0 µl 
MDA-231 genomic DNA, 0.2 µl Taq polymerase, 4 µl buffer, and 12.4 µl water. This 
solution was then placed in the thermocycler and 8 reaction tubes were run for 8 cycles.  
Restriction Digestion 
 
 In order to insert the miR-30c1 PCR amplicon into pTRE-Tight-DsRed2, 
restriction enzymes SmaI and NheI were used which create blunt ends.  1.0 µl of miR-
30c1 DNA along with 1.0 µl each of the restriction enzymes, 5 µl NEB Buffer 4 and 41.5 
µl water was incubated at 25°C (room temperature) for half an hour. Then this was 
removed and placed in a 37°C water bath for one hour. 
 Another restriction digest was performed in conjunction with the aforementioned 
digest to test whether the miR-30c1 insert was correct.   In this case, restriction enzymes 
XbaI and NheI were used because of their known cut sites on the plasmid. The miR-30c1 
amplicon DNA was combined with the restriction enzymes, BSA, and NEB Buffer, and 
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placed into a 37°C water bath for one hour. This was then analyzed on a1.0% agarose gel 
to verify the correct size (500 bp). 
 
Ligation 
 Once the insert was verified to be miR-30c1, the insert was ligated to the cut 
pTRE plasmid.  5 µl of the miR-30c1 DNA was combined with 5 µl of pTRE-Tight-
DsRed2 that had been cut during the double digest, 10 µl of the 2x quick ligation buffer 
and 1 µl of t4 quick DNA ligase. This was incubated at room temp for ½ hour.   
 
Transformation 
 For the transformation, DH5α E. coli cells were used.  LB+Ampicillin plates were 
placed in the 37°C incubator to be warmed for the cell spreading. Then 1.0 µl of ligation 
reaction was placed into 50 µl DH5α cells and 250 µl S.O.C. media. This solution was 
placed into snap-cap tubes and then was transferred to a floor shaker at 37°C for one 
hour. Afterwards the tubes were removed; the LB+Ampillicin plates were taken from the 
incubator and placed on the lab bench in a sterile area where the cells could be spread on 
the plates. Varying concentrations were plated: 50 µl, 100 µl, 150 µl and 200 µl to find 
the best colony growth. These plates were then placed in the 37°C incubator for 24 hours. 
 
Screening of the miR-30c1-pTRE-Tight-DsRed2 Plasmid 
 
 Colonies were picked from the 150 µ1 and 100 µl plates since they had many 
colonies to choose from, and the plate was not completely covered in colonies and 
satellite colonies.  Eight colonies were picked, and each was combined with 20 µl buffer, 
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6 µl MgCl2, 32 µl dNTPs, 4 µl of both forward and reverse primer, 5 µl, 1 µl Taq 
polymerase and 117 µl dH2O (for 8 reactions).  
 The positive control for this screening was the MDA-231 genomic DNA which 
was also combined with the aforementioned reagents. The negative control was the 
empty vector (without the ligated miR-30c1) and it was also combined with the PCR 
mixture. These solutions were transferred to PCR tubes and then placed in the 
thermocycler for one hour.  After the thermocycler completed its 8 cycles, a 1.0% 
agarose gel was made containing ethidium bromide and the samples were loaded into the 
gel.  After the bands ran about ¾ of the way down the gel, the gel was photographed 
using UV light.  The presence of miR-301c amplicons from the cloned plasmids indicated 
positives.  Positive colonies identified from the screen were frozen as 50% glycerol 
stocks at -80ºC. 
 
Plasmid Maxi Preps for Transfections 
In order to prepare sufficient clean quantities of the cloned plasmid miR-30c1-
pTRE-Tight-DsRed2 for transfection experiments, maxi preps were prepared.  Two 
LB+Amp plates were placed in the incubator and a tube containing a positive culture 
screened in the previous section was thawed. After the plates were warmed, they were 
moved to a sterile area, and streaked with 50 µl or 150 µl of culture.  Plates were returned 
to the 37°C incubator for 24 hours. 
  After the incubation, two fresh individual colonies were picked from the 50 µl 
plate and placed in 5 ml S.O.C. media in a snap-cap tube, and then placed in the floor 
shaker for 8 hours at 37°C. LB media with ampicillin was made for the next step of the 
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growing up of the plasmid. After this incubation period, the tubes were removed and the 
contents were each placed in 500 ml of LB media in Erlenmeyer flasks and returned to 
the 37 °C floor shaker for 24 hours. After this incubation, the media was split into 250 ml 
portions, spun down in a centrifuge, and the supernatant was removed, leaving the cell 
pellet. Then the two pellets from the same colony were recombined. 
 After the recombination of pellets, a maxi prep was performed using the Quiagen 
Maxi Prep Kit to extract the DNA grown up in the cells. These samples were placed in 
the spectrometer to find the concentration of the plasmid.  The highest concentration of 
the two samples was 120 µg/ml.  
 
Transient Transfections 
 
Growth of the Cell Lines 
 The cell lines that were used the transfections were human embryonic kidney cell 
line (HEK-293) and human-derived breast cancer cell line (MDA-231). The HEK-293 
cell line was chosen because it is easy to grow and manage. The first transfection is of the 
HEK-293 cells, the second transfection is of the MDA-231 cells. 
 
Transfection of the HEK-293 Cell Line  
  After the successful Maxi Prep, the HEK-293 cells were split for the transfection. 
The cells were count using trypan blue and a hemacytometer, and the needed amount per 
well of the 6-well plate was 3.5 x 10
5
 cells. The amount of volume was calculated based 
on the amount of cells available, 3.75 x 10
6
 and the needed volume of cells and 2 ml 
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media per well were placed in each well of the transfection plates and these were grown 
overnight.  
 In order to do the transfection, Fugene, a chemical that allows the plasmid to be 
taken in by the cells was used to successfully deliver the plasmid into our cell line. Rev-
tet off was also used to have miR-30c1 constitutively expressed in the cells since at this 
point we did not know what would happen to the cells if high levels of miR-30c1 were 
present. The control for this transfection was one well containing only cells and not the 
transfection agents. The other wells had varying concentrations of the miR-30c1:  0.01 
µg, 0.5 µg, 1.0 µg, 1.5 µg and 2.0 µg. After the transfection, these plates were placed into 
a 37°C incubator for 48 hours. 
qRT-PCR of the HEK-293 Transfection 
 
 Following transfection, total cellular RNA was isolated from the cells by using 
the PARIS kit, provided by Ambion Systems.  In order to quanitate the cellular levels of 
miR-30c1 RNA in the cells, a qRT-PCR was performed. The primers used in this assay 
were TaqMan.  For each 15 µl reaction, the ratio of RT master mix to total RNA is 7 µl to 
5 µl. We used 10 ng of cellular RNA diluted to 2ng/µl.  Thus 5 µl was used of RNA, 3 µl 
of primer and 7 µl RT master mix. After everything was combined, the solution was 
transferred to PCR tubes and placed in the thermocycler for 65 min.  
 Once the cDNA was made, the RT product, primer, master mix, and water were 
calculated for 10 µl reactions and for each concentration miR-30c1 performed in 
triplicate. Thus a 384-well plate was needed for the loading control, U6, miR-30c1 and 
miR-30e (miR-30e was another test), a total of 99 samples. Table I shows the calculations 
and how the 384-well plate was loaded. 
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Reagents 
96-well plate (20 µl per 
reaction) 
384-well plate (10 µl per 
reaction)  
Primer 1 µl 0.5 µl 
RT Product 1.33 µl 0.67 µl 
Master Mix 10 µl 5 µl 
Nuclease Free 
Water 7.67 µl 3.83 µl 
 
Table 1: Reagent Calculations for RT-PCR.  This RT-PCR 
amplification was performed for 120 reactions  
 
Transfection of the MDA-231 Cell Line 
 For this transfection, pTet-On was used to control the cellular levels of miRNA 
expression within the cells and to optimize the tet-responsive element in the plasmid. The 
pTet-On had been ligated with the pTRE-Tight-DsRed2 plasmid and was combined with 
DH5α cells for the transformation. Two LB+Amp plates were placed in the 37°C 
incubator. After the plates were warmed, they were streaked with 50 µl or 150 µl of cell 
suspension. These were returned to the 37°C incubator for 24 hours.   After the 
incubation, two fresh individual colonies were picked from the 50 µl plate and used to 
prepare a maxi-prep as described previously, except 500 ml cultures were used. The 
highest concentration from the four samples was 450 µg/ml.  
 After the successful Maxi Prep, the MDA-231 cells were split for the transfection. 
The cells were counted using trypan blue and a hemacytometer.  The needed amount of 
cells for a 6-well plate was 3.5 x 10
5
 cells per well, so the volume was calculated based 
on the amount of cells available, 3.67 x 10
5
 and 1.97 x 10
5
, which were taken from the 
total collection of MDA-231 plates. The required volume of cells and 2 ml of media per 
well were placed in each well of the transfection plates and these were grown overnight. 
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One of the six-well plates was dedicated to controls, and the other plate was the 
experimental plate. 
 As described before, Fugene was used to deliver the plasmid into the cell line. 
The controls for this experiment were a cells-only well, an empty vector that did not 
contain miR-30c1 well, fugene-only well, and the plasmid without PTet-On. The other 
wells had varying concentrations of the pTet-On-pTRE-Tight-DsRed2 plasmid: 0.5 µg, 
1.0 µg, 1.5 µg, and 3.0 µg. After the transfection, these plates were placed into a 37°C 
incubator for 48 hours.  
To induce the TRE-plasmids with Dox, the highest recommended dose of 
doxycycline was added to each of the wells, which was 1.5 µl per well. After the 
induction with doxycycline, the cells were incubated for one hour then observed under 
the fluorescent microscope for the presence of the red DsRed2 reporter. 
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RESULTS 
 
 
 The purpose of this project was to create a tet-regulated system for the expression 
of different types of miR-30 RNAs (miR-30c1, c2, a, and d) in HEK-293 and MDA-231 
cells.   The miR-30 family in general was chosen for investigation because their seed 
sequences are predicted to bind mRNAs for RUNX2 and metadherin, two metastasis 
inducing genes.  The family was also selected because of its presence in the lab’s double 
and triple negative mouse breast cancer models, and its presence in spindloid and 
adenocarcinoma tumors.  In particular, miR-30c1 was chosen for over-expression due to 
its low levels in spindloid tumors.   
 The first step in the process of making the tet-regulated expression system was to 
select a plasmid that could be taken up by the cells and regulate the amount of miRNA 
present for future assays. The plasmid chosen was ClonTech’s pTRE-Tight-DsRed2, 
because of its built-in reporter gene, TRITC, which encodes the red fluorescing protein 
DsRed2, and its tet-responsive element (TRE) promoter, which allows for tet-regulation. 
The process also uses a sister plasmid that expresses the tetracycline transactivator (tTA) 
in the presence of tetracycline or doxycycline.  The tTA binds the TRE element of the 
first plasmid to switch on expression of both the miR-30c1 and the DsRed2 
 DNA encoding four miR-30’s (c1, c2, a, d) were cloned from MDA-231 genomic 
DNA by PCR. The amplicons were cut with restriction enzymes to verify they 
represented miR-30 DNA.  To clone the DNAs into the TRE expression vector, the 
DNAs were cut with enzymes to produce blunt ends for cloning.  The blunt  ended DNAs 
were ligated into the TRE plasmid, and positives were screened by restriction digestion to 
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remove insert (Figure-9).  The data indicated the successful cloning of all four miR-30 
DNAs.   
 
 
Figure-9: PCR Screening of Positive TRE Plasmids Encoding Four miR-30 RNAs.  These are the gel 
electrophoresis results of transformation of the miR-30 of interest and pTRE-Tight-DsRed2 into DH5α 
cells. Panel A represents positive results for miR-30a and miR-30c2. Panel B represents positive results for 
miR-30c1. Panel C represents positive results for miR-30a, miR-30c2 and miR-30d. The positive control for 
all of these gels was the MDA-231 genomic DNA as indicated by the plus sign. The negative control for all 
of the gels is the vector without insert. 
 
 
 Two cell lines were chosen for transfection, human embryonic kidney cells 
(HEK-293) and human derived breast cancer cells (MDA-231).   HEK-293 cells were 
used first to test whether the clones could increase the detectable amount of miR 
expression.  The plasmid encoding miR-30c1 was chosen for transfection, at various 
masses of plasmid (Figure-10).    
 
 
Figure-10: Diagram of the 6-Well Plate Setup for the miR-30c1 
Transfection Experiment.  This is the 6-well transfection plate with 
the varying concentrations of miR-30c1 plasmid. Each well contained 2 
ml of media, and a ratio of 2:3 DNA to Fugene per well. They also all 
contained the same amount of Rev-Tet Off to have the cells 
constitutively express miR-30c1. 
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 Table II shows the amounts of each reagent used for the transfections.  Rev-Tet-
Off is a plasmid encoding an inactive tTA and it was used to temporarily suppress 
expression of the miR since its effects on cell growth are unknown and could be 
detrimental to the cell.   
Reagent Well 2 Well 3 Well 4 Well 5 Well 6 
Rev-Tet off 1.26 µl 1.26 µl 1.26 µl 1.26 µl 1.26 µl 
MiR-30 c1 0.1 µg 0.5 µg 1.0 µg 1.5 µg 2.0 µg 
Fugene 2.4 µl 3 µl 3.75 µl 4.5 µl 5.25 µl 
Media 100 µl 100 µl 100 µl 100 µl 100 µl 
 
Table II: Reagents Added for Transfection.  This is the calculated 
reagents per well. The concentration of Rev-Tet off is 1.19 µg/µl and 
the concentration of miR-30c1 is 120 µg/ml. 
 
  
 After 48 hours of incubation, the plates were examined under the fluorescent 
microscope to see if the cells had taken up the plasmid, as indicated by the red 
fluorescing reporter DsRed2 (TRITC) (Figure-11). The data indicate that approximately 
30% of the cells had taken up the TRE miR-30c1 plasmid in the transfection (note that the 
red fluorescent signal is white in the figure).   
 
Figure-11: Fluorescence Microscopy of HEK-293 Cells Transfected 
with TRE Plasmid Encoding miR-30c1.  The data indicate that 
approximately 30% of the cells had taken up plasmid. 
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To determine whether the transfected cells increased their levels of miR-30c1 
RNA, total RNA was isolated from the cells, and qRT-PCR was performed using miR-30 
primers (Figure-12).  Due to the large number of samples, a 384-well plate was used in 
the real-time portion of the PCR. The loading control was U6, a small RNA constitutively 
expressed in the cell; it is quanitated to ensure the same amount of RNA is in each 
sample.  The cellular levels of expression were normalized relative to the amount of U6 
in each sample. The data indicate an increase of miR-30c1 RNA in cells transfected with 
plasmid, especially at the 1.5 µg dose.  A 0.1 µg sample is missing because it was 
contaminated during the transfer to create a triplicate.  The expression levels diminished 
at the highest dose tested. 
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Figure-12: qRT-PCR Assay of the Levels of miR-30c1 in Transfected Hek-293 C. The upper panel 
denotes raw OD data, while the lower panel denotes the data normalized relative to untransfected cells. As 
seen in this graph, detectable levels of miR-30c1 increased relative to non-transfected cells, especially in the 
1.5 µg DNA sample. The lowering of expression observed in the 2.0 µg concentration could attribute to 
that the cells can only withstand a certain amount of miR-30 and an overloading of the system may have 
occurred.  All miR-30c1 levels were normalized relative to U6 small RNA. 
 
 
In order to test whether over-expression of miR-30c1 induced the expression of 
another miR-30 RNA, primers to miR-30b were used in qRT-PCR (Figure-13).  The data 
indicate surprisingly that the levels of miR-30b did increase, and were maximal in the 
cells maximally expressing miR-30c1.  
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Figure-13: qRT-PCR Analysis of the Cellular Levels of miR-30b in HEK-293 Cells Overexpressing 
miR-30c1. This graph represents the cellular levels of expression of miR-30b. The upper panel denotes the 
raw OD data, while the lower panel denotes the data normalized relative to untransfected cells. Note that its 
expression is highest at the same 1.5 µg plasmid dose that gave the maximal miR-30c1 expression. 
 
  
 The next test was to determine whether the miR-30c1 expression could be 
controlled within the cells using the tet-responsive element of the plasmid.  By co-
transfecting the pTet-On plasmid, encoding a Tet or Dox activatable tTA which would 
bind the TRE of the miR plasmid inducing its expression, a system was created for an 
inducible miR system.  The plate setup for the transfection consisted of one control plate 
(Figure-14) and one experimental plate (Figure-15).  
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Figure-14: Diagram of the Control 6-well Transfection Plate. The 
amount of Fugene used in the fugene well was the maximum 
recommended amount which was 6.75 µl. The amount of the plasmid 
without the ligated miR-30 c1 is 1.5 µg. The amount of plasmid without 
PTet-On is 3.0 µg which was the maximum used in our experimental 
plate. Each well contained 2 ml of media, and a ratio of 2:3 DNA to 
Fugene per well. The last two wells were cells only. 
 
 
 
 
Figure 15: Diagram of the Experimental 6-well Transfection Plate. 
The varying concentrations represent the concentrations of miR-30c1-
DsRed2 plasmid. Each well contained 2 ml of media, and a ratio of 2:3 
DNA to Fugene per well. The last well was cells only. 
 
 
 E. coli cells containing plasmid pTet-On were streaked on plates in 50 µl and 150 
µl concentrations, then fresh individual colonies were picked, grown in SOC media, then 
in LB + Ampicillin media.  The Qiagen Maxi Prep procedure was performed to extract 
and purify the plasmid DNA, and the final concentration was found to be 450 µg/ml.  3.5 
x 10
5 
MDA-231 cells were seeded per well, and the transfection was set-up as described 
in Table III.  1.5 µg of pTet-On (3.33 µl) was added per well.  
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Reagent Well 1 Well 2 Well 3 Well 4 
mir-30c1-DsRed2 0.5 µg 1.0 µg 1.5 µg 3.0 µg 
Fugene 3 µl 3.75 µl 4.5 µl 6.75 µl 
PTet-On 3.33 µl 3.33 µl 3.33 µl 3.33 µl 
Media 100 µl 100 µl 100 µl 100 µl 
 
Table III: Transfection Setup for the Double Transfection pTRE-
miR-30c1 + pTet-On Experiment.  Shown are the calculated reagents 
per well. The concentration of PTet-On is 0.45 µg/µl, and the 
concentration of miR-30c1 is 120 µg/ml. 
 
 
 After 24 hours incubation, doxycycline was added to all of the experimental wells 
to activate the tet-responsive element of the plasmid. After one hour, both plates were 
observed for expression. Unfortunately none of the wells showed any expression, which 
would have been indicated by red fluorescence. The pictures of the fluorescence were just 
black screens.  We did not proceed with the qRT-PCR because of these negative results. 
This experiment was not repeated in HEK-293 cells which had shown the previous 
successful fluorescence data. 
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DISCUSSION 
 
 
 The data from this project show that a system to express miR-30c1 was 
successfully constructed.  Fluorescence microscopy on transfected HEK-293 cells 
indicated strong expression of the marker protein DsRed2, and qRT-PCR on transfected 
HEK-293 RNA indicated strong expression of miR-30c1.  Thus it is possible to make a 
system in which miR-30 plasmid can be transported into cells.  This procedure may not 
be as effective as direct transfection of the synthetic oligos, but this comparison was not 
tested in this project.  However plasmid transfection is a cost-effective tool and will be 
optimized in the future to achieve higher levels of expression. Also when the assay 
becomes optimized eventually a stable cell line can be created to produce a system that 
continuously expresses miR-30c1, which is not possible with synthetic oligos. 
 The main problems with this project were the initial cloning, and the transfection 
of the MDA-231 cell line. The issue with cloning was that an initial vector (FIV 
plasmid), was not efficiently transformed into DH5α cells. The screening repeatedly 
came out negative, and when there was a slight positive result it did not pan out on 
subsequent screening.  It was thought that the E. coli cells were being killed off by the 
plasmid.  So a new plasmid was chosen, the pTRE-Tight-DsRed2 which included a built 
in reporter and had the tet-responsive element.  Cloning was successful with this plasmid 
as was the primary transfection in HEK-293 cells.  
But when performing the MDA-231 transfection, we only tested one amount of 
doxycycline, and it was unclear how much pTet-On should have been used per well since 
it was unknown how much pTet-On could be detrimental to the MDA-231 cells. There 
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may have been too much PTet-On and doxycycline in the system and it killed off the 
cells, or there may have been too little, and there were not sufficient quantities of plasmid 
to fluoresce.   Concentrations that were used in this transfection were based off of the 
HEK-293 transfection since it yielded positive results at certain concentrations of miR-
30c1.  In addition, HEK-293 cells are traditionally easy to transfect, so it is possible that 
the MDA-231 cells are simply more resistant to transfections.  Time did not allow us to 
repeat the tet experiment in HEK-293 cells. 
 For future experiments, we want to optimize the transfection and find out how 
much doxycycline and PTet-On is sufficient for the plasmid to be expressed.  More 
concentration tests of the plasmid could be performed in conjunction with exploration on 
the amount of doxycycline.  This could be done with more transfections of the MDA-231 
cell line (and also the easier to transfect HEK-293 line) and then analyzed with qRT-
PCR. 
 Another future experiment would be to create stable transfectants for 
constitutively producing miR-30c1 to determine its long term effects on the cell.  These 
experiments are not possible when directly transfecting oligos because the oligos are 
eventually degraded.  With the stable cell line, time-point assays could be performed 
since the cells could replicate and retain the plasmid in their genome. Such assays that 
could be done to gain insight of the functions of miR-30’s, since it is unknown how miR-
30’s play a role in tumor oncogenesis, and assays that could be performed are 
proliferation and invasive assays to see how they might act as an oncogene or tumor 
suppressor.  
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 Lastly we could use qRT-PCR and western blots to investigate whether RUNX2 
or metadherin mRNAs or proteins, respectively, are downregulated in cells 
overexpressing miR-30c1.  These two target genes have been predicted to bind the seed 
sequences of miR-30 family members using Target Scan software. 
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